Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study.
Open Access CRIS of the University of Bern · 08.04.2024
DOI: 10.48350/195862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 08.04.2024. Verfasst von Philipp C. Lurz und 55 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUND Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes with the PASCAL system in a post-market setting have not been established. OBJECTIVES The authors report 30-day and 1-year outcomes from the MiCLASP (Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System) European post-market clinical follow-up study. METHODS Patients with symptomatic, clinically significant MR were prospectively enrolled. The primary safety endpoint was clinical events committee-adjudicated 30-day composite major adverse event rate and the primary effectiveness endpoint was echocardiographic core laboratory-assessed MR severity at discharge compared with baseline. Clinical, echocardiographic, functional, and quality-of-life outcomes were assessed at 1 year. RESULTS A total of 544 patients were enrolled (59% functional MR, 30% degenerative MR). The 30-day composite major adverse event rate was 6.8%. MR reduction was significant from baseline to discharge and sustained at 1 year with 98% of patients achieving MR ≤2+ and 82.6% MR ≤1+ (all P < 0.001 vs baseline). One-year Kaplan-Meier estimate for survival was 87.3%, and freedom from heart failure hospitalization was 84.3%. Significant functional and quality-of-life improvements were observed at 1 year, including 71.6% in NYHA functional class I/II, 14.4-point increase in Kansas City Cardiomyopathy Questionnaire score, and 24.2-m improvement in 6-minute walk distance (all P < 0.001 vs baseline). CONCLUSIONS One-year outcomes of this large cohort from the MiCLASP study demonstrate continued safety and effectiveness of M-TEER with the PASCAL system in a post-market setting. Results demonstrate high survival and freedom from heart failure hospitalization, significant and sustained MR reduction, and improvements in symptoms, functional capacity, and quality of life.
Schlagwörter
Zitieren
APA
Lurz, P. C., Schmitz, Thomas, Geisler, T., Hausleiter, Jörg, Eitel, Ingo, Rudolph, Volker, Lubos, E., Bardeleben, R. S. V., Brambilla, N., Marco, D., Federico, Berti, Sergio, NEF, H. M., Linke, A., …, & Luedike, P. (2024). Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study. Open Access CRIS of the University of Bern. https://doi.org/10.48350/195862
Vancouver
Lurz PC, Schmitz, Thomas, Geisler T, Hausleiter, Jörg, et al. Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study. Open Access CRIS of the University of Bern. 2024. doi:10.48350/195862
BibTeX
@article{Lurz2024,
author = {Lurz, Philipp C. and Schmitz and Thomas and Geisler, Tobias and Hausleiter and Jörg and Eitel and Ingo and Rudolph and Volker and Lubos, Edith and Bardeleben, Ralph Stefan von and Brambilla, Nedy and Marco, De and Federico and Berti and Sergio and NEF, HOLGER M. and Linke, Axel and Hengstenberg and Christian and Baldus and Stephan and Spargias and Konstantinos and Denti, Paolo and Nickenig and Georg and Möllmann, Helge and Rottbauer and Wolfgang and Praz, Fabien and Butter and Christian and Reinthaler, Markus and Mieghem, Van and M, Nicolas and Sherif, Mohammad and Swaans and Martin and Witkowski and Adam and Buch, Mamta Heena and Seidler, Tim and Iñiguez and Andrés and Thiele, Holger and Eißmann, Mareike and Schreieck, Jüergen and Näbauer and Michael and Marcoff, Leo and Koulogiannis, Konstantinos P. and Rassaf and Tienush and Luedike, Peter},
title = {Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study},
journal = {Open Access CRIS of the University of Bern},
year = {2024},
doi = {10.48350/195862}
}
EUVIMED